vs

Side-by-side financial comparison of Applied Therapeutics, Inc. (APLT) and ZenaTech, Inc. (ZENA). Click either name above to swap in a different company.

Applied Therapeutics, Inc. is the larger business by last-quarter revenue ($1.0M vs $941.9K, roughly 1.1× ZenaTech, Inc.).

Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.

ZenaTech, Inc. is a technology firm specializing in AI-integrated drone solutions and enterprise SaaS platforms for industrial and public sector clients. Its core offerings include purpose-built drone hardware, fleet management tools, and actionable data analytics, serving key markets such as public safety, infrastructure inspection, agriculture, and logistics across North America.

APLT vs ZENA — Head-to-Head

Bigger by revenue
APLT
APLT
1.1× larger
APLT
$1.0M
$941.9K
ZENA

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
APLT
APLT
ZENA
ZENA
Revenue
$1.0M
$941.9K
Net Profit
$-19.0M
Gross Margin
Operating Margin
-1675.8%
Net Margin
-1899.0%
Revenue YoY
719.7%
Net Profit YoY
72.3%
EPS (diluted)
$-0.13
$-0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APLT
APLT
ZENA
ZENA
Q3 25
$1.0M
$941.9K
Q2 25
$0
$702.6K
Q1 25
$0
$431.7K
Q4 24
$-1.0K
Q3 24
$820.1K
Q2 24
$144.0K
Q1 24
$190.0K
Q4 23
$-667.0K
Net Profit
APLT
APLT
ZENA
ZENA
Q3 25
$-19.0M
Q2 25
$-21.3M
Q1 25
$-21.8M
Q4 24
$44.0M
Q3 24
Q2 24
$2.9M
Q1 24
$-83.9M
Q4 23
$-37.7M
Operating Margin
APLT
APLT
ZENA
ZENA
Q3 25
-1675.8%
Q2 25
Q1 25
Q4 24
3302300.0%
Q3 24
Q2 24
-14194.4%
Q1 24
-11101.6%
Q4 23
3149.3%
Net Margin
APLT
APLT
ZENA
ZENA
Q3 25
-1899.0%
Q2 25
Q1 25
Q4 24
-4400700.0%
Q3 24
Q2 24
2012.5%
Q1 24
-44177.9%
Q4 23
5649.0%
EPS (diluted)
APLT
APLT
ZENA
ZENA
Q3 25
$-0.13
$-0.49
Q2 25
$-0.15
$-0.01
Q1 25
$-0.15
Q4 24
$0.52
Q3 24
Q2 24
$-0.13
Q1 24
$-0.67
Q4 23
$-0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APLT
APLT
ZENA
ZENA
Cash + ST InvestmentsLiquidity on hand
$11.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$-561.0K
Total Assets
$34.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APLT
APLT
ZENA
ZENA
Q3 25
$11.9M
Q2 25
$30.4M
Q1 25
$50.8M
Q4 24
$79.4M
Q3 24
Q2 24
$122.2M
Q1 24
$146.5M
Q4 23
$49.9M
Stockholders' Equity
APLT
APLT
ZENA
ZENA
Q3 25
$-561.0K
Q2 25
$17.4M
Q1 25
$36.7M
Q4 24
$57.0M
Q3 24
Q2 24
$72.4M
Q1 24
$67.3M
Q4 23
$-17.1M
Total Assets
APLT
APLT
ZENA
ZENA
Q3 25
$34.4M
Q2 25
$37.3M
Q1 25
$56.9M
Q4 24
$86.7M
Q3 24
Q2 24
$127.8M
Q1 24
$151.2M
Q4 23
$54.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APLT
APLT
ZENA
ZENA
Operating Cash FlowLast quarter
$-18.4M
$-3.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APLT
APLT
ZENA
ZENA
Q3 25
$-18.4M
$-3.1M
Q2 25
$-20.3M
$-941.0K
Q1 25
$-28.6M
$-396.2K
Q4 24
$-19.5M
Q3 24
$-3.1M
Q2 24
$-22.6M
Q1 24
$-18.9M
Q4 23
$-17.0M
Cash Conversion
APLT
APLT
ZENA
ZENA
Q3 25
Q2 25
Q1 25
Q4 24
-0.44×
Q3 24
Q2 24
-7.80×
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons